ORIC Pharmaceuticals’ (ORIC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock. HC Wainwright also issued estimates for ORIC Pharmaceuticals’ Q2 2025 earnings at ($0.55) EPS and Q3 2025 earnings at ($0.57) EPS.

A number of other equities analysts have also issued reports on ORIC. Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Monday, September 23rd. Wells Fargo & Company assumed coverage on ORIC Pharmaceuticals in a research report on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $18.29.

ORIC Pharmaceuticals Stock Performance

NASDAQ ORIC opened at $10.87 on Monday. The stock’s 50 day simple moving average is $9.01 and its 200 day simple moving average is $9.46. ORIC Pharmaceuticals has a one year low of $6.33 and a one year high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.01). As a group, equities research analysts forecast that ORIC Pharmaceuticals will post -1.84 EPS for the current fiscal year.

Insider Buying and Selling at ORIC Pharmaceuticals

In related news, insider Pratik S. Multani sold 8,850 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,278.00. Following the sale, the insider now directly owns 46,765 shares in the company, valued at $387,214.20. This trade represents a 15.91 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Dominic Piscitelli sold 8,851 shares of ORIC Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $73,286.28. Following the transaction, the chief financial officer now directly owns 106,764 shares in the company, valued at $884,005.92. The trade was a 7.66 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,361 shares of company stock worth $350,749. Insiders own 5.55% of the company’s stock.

Hedge Funds Weigh In On ORIC Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC grew its stake in ORIC Pharmaceuticals by 253.2% in the second quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock valued at $73,000 after acquiring an additional 7,440 shares during the period. Creative Planning bought a new position in shares of ORIC Pharmaceuticals during the 3rd quarter valued at about $116,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of ORIC Pharmaceuticals in the 3rd quarter valued at approximately $132,000. China Universal Asset Management Co. Ltd. increased its stake in ORIC Pharmaceuticals by 71.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock worth $139,000 after purchasing an additional 5,646 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in ORIC Pharmaceuticals during the 2nd quarter worth approximately $153,000. 95.05% of the stock is owned by institutional investors.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.